Phase 0/I Study of AMG 232 Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2019
Price : $35 *
At a glance
- Drugs AMG 232 (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions; Pharmacokinetics
- 09 Jul 2019 Planned End Date changed from 30 Jun 2019 to 30 Jun 2020.
- 09 Jul 2019 Planned primary completion date changed from 30 Jun 2019 to 30 Jun 2020.
- 13 Feb 2019 Status changed from suspended to recruiting.